bluuebunny/crossref_metadata_2025_split huggingface dataset:
Revisiting Wansbrough’s Perspective on the Qurʾān’s Synoptic Problem
Authors: Moqbel Tareq 
Published: December 2022

Abstract
The occurrence of variant versions of the same story is not uncommon in the Qurʾān. In response to this phenomenon, different approaches have been developed; one of which was Wansbrough’s variant traditions hypothesis. The hypothesis, which emerged mainly from an analysis of three accounts of the prophet Shuʿayb’s story in the Qurʾān, posits that the different tellings of the same story existed as independent pericopes that later found their way into the text of the Qurʾān, a claim that has many implications on the authorship and composition of the Qurʾān. Consequently, the reactions to this hypothesis were varied. In this paper, I present one of the critiques to the hypothesis, that of Stewart. Then, I employ elements of textual criticism to provide further ways for viewing the variant traditions. I do this by drawing attention to empirical evidence from the Near East, pre-Islamic poetry, orality theory, and to some of the internal characteristics of the Qurʾān. The general conclusion is neither surprising nor new: Wansbrough’s findings regarding the genealogy of the variant traditions and the authorship of the Qurʾān are far from self-evident.
2. Let’s Go Shopping
Authors: Gutiérrez Fanny , Rodríguez Yael 
Published: December 2022

“Let’s Go Shopping” is a landscape of investigation about economic and financial education framed by the sociocritical perspective of mathematical modelling. The landscape developed as a result of discussions among students from a school in Bogotá about high-interest charges and loans. Our aim was to identify possibilities and challenges in the use of a sociocritical
perspective on mathematical modelling when promoting citizenship education. To do this, we addressed the discussions by the students and considered students’ intentions, backgrounds, and foregrounds. The landscape included investigations of families’ economic conditions, as the students related the mathematics classroom activities to their families’ financial issues.
5. Mathematics Embedded in Community-Based Practices
Authors: Bose Arindam 
Published: December 2022

Low-income settlements with diverse income-generating work practices dispersed among households create opportunities and affordances for learning, which have mathematical elements embedded in them. Drawing from the community’s rich knowledge resource (funds of knowledge), children from the neighbourhood learn to assimilate knowledge, competence, and skills. Out-of-school mathematical knowledge equips them to handle complex situations calling for quick decision-making and optimising resources and profits. Deals are negotiated following several variables, and cases of unjust wages and payments are aplenty. This chapter argues that such backdrops could form landscapes of investigation, and that the handling of or limited access to diverse goods—as well as the optimising of resources and decision-making processes—create different possibilities for not just dealing with mathematical knowledge but also questioning unfair work deals and examining social injustice. Such landscapes of investigation provide direction beyond the exercise paradigm,
towards an enabling pattern of critical communication.
15. The Investigative Approach to Talking about Inclusion in Mathematics Teacher Education
Authors: Dias Barros Denner 
Published: December 2022

Looking at the range of diversity in the classroom is a necessary task for the teacher who seeks to teach from an inclusive perspective. More and more educational legislation has been authorised so that all students can have access to quality education. The use of landscapes of investigation in mathematics teacher education could become a practice that helps prospective teachers to reflect on future practices by taking into consideration the diversity of school contexts. In this chapter, reflections are made on the practices of two research projects, one for a doctorate and another for a Master’s degree. Working with investigative projects allowed prospective teachers to think about practices that take into account the particularities of this diversity. Furthermore, the dialogic perspective is highlighted as being essential in this process, as well as the ideas and visions of the prospective teachers invited
to participate in their own professional education. It is hoped that this chapter can inspire prospective teachers to develop critical activities that allow for the participation of all students.
Molecular simulation of the adsorption of the hydration inhibitor N1,N1’-(ethane-1,2-diethyl)bis(N1-(2-aminoethyl)ethane-1,2-diamine onto montmorillonite
Authors: Yuan Shi , Zhao Xin , Cheng Rongchao , Qu Yuanzhi , Xue Jiawen , Li Yiang , Sun Jinsheng , Xu Jiafang 
Published: December 2022

AbstractClay-swelling inhibitors are often used to prevent the hydration of clay minerals, which can reduce the risk of wellbore instability and reservoir damage. The molecular behaviour of clay-swelling inhibitors at the montmorillonite–water interface is crucial for revealing their inhibition mechanisms and for evaluating and designing inhibitor molecules. N1,N1'-(ethane-1,2-diyl)bis(N1-(2-aminoethyl)ethane-1,2-diamine) (NETS), a low-molecular-weight clay-swelling inhibitor, is used widely to prevent clay swelling. Herein, the adsorption mechanism of NETS on the surface of montmorillonite (Mnt) was investigated using molecular dynamics (MD) simulations. In particular, the effects of molecular conformation and temperature on adsorption ability were investigated. The results show that the adsorption ability of NETS on the Mnt surface was affected significantly by the molecular conformation. Specifically, the dihedral angle of NETS adsorbed on the surface of Mnt decreases by ~20° and tends to adsorb on the surface of Mnt in a plane state. In addition, the adsorption stability of NETS on the Mnt surface decreased with increasing temperature, as was found using MD simulations. Detailed analysis shows that increasing temperature can lead to more frequent conformational changes, which weaken the interaction between NETS and Mnt, thus reducing adsorption stability. These molecular insights into the interaction mechanism between NETS and Mnt are beneficial for the evaluation of inhibitory effects and for the selection and molecular design of new clay-swelling inhibitors for use in drilling fluids.
The histone methyltransferase MLL1/KMT2A in monocytes drives coronavirus-associated coagulopathy and inflammation
Authors: Sharma Sriganesh B. , Melvin William J. , Audu Christopher O. , Bame Monica , Rhoads Nicole , Wu Weisheng , Kanthi Yogendra , Knight Jason S. , Adili Reheman , Holinstat Michael A. , Wakefield Thomas W. , Henke Peter K. , Moore Bethany B. , Gallagher Katherine A. , Obi Andrea T. 
Published: December 2022

Abstract
Coronavirus-associated coagulopathy (CAC) is a morbid and lethal sequela of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. CAC results from a perturbed balance between coagulation and fibrinolysis and occurs in conjunction with exaggerated activation of monocytes/macrophages (MO/Mφs), and the mechanisms that collectively govern this phenotype seen in CAC remain unclear. Here, using experimental models that use the murine betacoronavirus MHVA59, a well-established model of SARS-CoV-2 infection, we identify that the histone methyltransferase mixed lineage leukemia 1 (MLL1/KMT2A) is an important regulator of MO/Mφ expression of procoagulant and profibrinolytic factors such as tissue factor (F3; TF), urokinase (PLAU), and urokinase receptor (PLAUR) (herein, “coagulopathy-related factors”) in noninfected and infected cells. We show that MLL1 concurrently promotes the expression of the proinflammatory cytokines while suppressing the expression of interferon alfa (IFN-α), a well-known inducer of TF and PLAUR. Using in vitro models, we identify MLL1-dependent NF-κB/RelA–mediated transcription of these coagulation-related factors and identify a context-dependent, MLL1-independent role for RelA in the expression of these factors in vivo. As functional correlates for these findings, we demonstrate that the inflammatory, procoagulant, and profibrinolytic phenotypes seen in vivo after coronavirus infection were MLL1-dependent despite blunted Ifna induction in MO/Mφs. Finally, in an analysis of SARS-CoV-2 positive human samples, we identify differential upregulation of MLL1 and coagulopathy-related factor expression and activity in CD14+ MO/Mφs relative to noninfected and healthy controls. We also observed elevated plasma PLAU and TF activity in COVID-positive samples. Collectively, these findings highlight an important role for MO/Mφ MLL1 in promoting CAC and inflammation.
Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice
Authors: Couvidou Adèle , Angénieux Catherine , Ruch Laurie , Mangin Pierre H. , Gachet Christian , Maître Blandine 
Published: December 2022

Abstract
Alloimmunization against platelets remains a potentially serious adverse transfusion event. Alloantibodies produced by the recipient, mainly directed against human leukocyte antigen class I donor antigens, can compromise the therapeutic efficacy of subsequent transfusions, and may lead to refractoriness. Because the mechanism of anti-HLA alloantibody formation is poorly understood, this study aimed to identify the cells involved in the platelet immune response by focusing on the spleen, the main organ that orchestrates this alloimmune response. In the spleen, transfused allogeneic platelets are located in the marginal zone and interact with marginal zone B (MZB) cells, a specialized B-cell population implicated in the capture and follicular delivery of blood-borne antigens. To study the involvement of MZB cells in alloantibody production, we used a murine model reproducing major histocompatibility complex incompatibility between a donor (H2b) and recipient (H2d) that occurs during platelet transfusion. Following weekly H2b platelet transfusions, recipient H2d mice produced anti-H2b immunoglobulin G, which induced a refractory state upon subsequent transfusions. Specific immunodepletion of MZB cells or their displacement from the marginal zone to the B-cell follicles by treatment with an S1P1 antagonist before each transfusion prevented significant alloantibody formation. Under these conditions, transfused platelets were still circulating after 24 hours, whereas they were rapidly removed from circulation in alloimmunized mice. The identification of MZB cells as key players in the platelet alloimmune response opens up new perspectives for minimizing platelet alloimmunization and avoiding the associated refractory state in frequently transfused patients.
Antibodies and bispecifics for multiple myeloma: effective effector therapy
Authors: Cipkar Christopher , Chen Christine , Trudel Suzanne 
Published: December 2022

Abstract
The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last 2 decades. With the introduction of novel immunotherapies, patients with MM can expect deeper responses, longer remissions, and improved overall survival. Since its approval by the US Food and Drug Administration in 2015, the monoclonal antibody specific for CD38, daratumumab, has been incorporated into both frontline and relapsed treatment regimens. Its role as a maintenance therapy is currently being explored. Subsequently, a variety of novel antibody therapeutics have evolved from the success of daratumumab, using similar concepts to target the malignant plasma cell clone. Noteworthy naked monoclonal antibodies include isatuximab, another agent directed against CD38, and elotuzumab, an agent directed against SLAM family member 7. Antibody-drug conjugates, complex molecules composed of an antibody tethered to a cytotoxic drug, target malignant cells and deliver a lethal payload. The first to market is belantamab mafodotin, which targets B-cell maturation antigen (BCMA) on malignant plasma cells and delivers a potent microtubule inhibitor, monomethyl auristatin F. Additionally, bispecific T-cell antibodies are in development that engage the immune system directly by simultaneously binding CD3 on T cells and a target epitope—such as BCMA, G-protein coupled receptor family C group 5 member D (GPRC5d), and Fc receptor homologue 5 (FcRH5)—on malignant cells. Currently, teclistamab, an anti-BCMA bispecific, is closest to approval for commercial use. In this review, we explore the evolving landscape of antibodies in the treatment of MM, including their role in frontline and relapse settings.
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts
Authors: Bewersdorf Jan Philipp , Rampal Raajit K. 
Published: December 2022

Abstract
The BCR-ABL-negative myeloproliferative neoplasms (MPNs) have a variable risk of progressing to accelerated- or blast-phase MPN (MPN-AP/MPN-BP), defined by the presence of 10% to 19% and more than or equal to 20% myeloid blasts in the peripheral blood or bone marrow, respectively. The molecular processes underlying the progression to MPN-AP/MPN-BP are becoming increasingly understood with the acquisition of additional mutations in epigenetic modifiers (eg, ASXL1, EZH2, TET2), TP53, the Ras pathway, or splicing factors (eg, SRSF2, U2AF1), having been described as important steps in this evolutionary process. At least partially driven by the enrichment of these high-risk molecular features, the prognosis of patients with MPN-BP remains inferior to other patients with acute myeloid leukemia, with a median overall survival of 3 to 6 months. Allogeneic hematopoietic cell transplantation remains the only potentially curative therapeutic modality, but only a minority of patients are eligible. In the absence of curative intent, therapeutic strategies or palliative treatment with hypomethylating agents as monotherapy or in combination with ruxolitinib or venetoclax can be considered. Several novel agents are in various stages of clinical development but are not available for routine use at this point, highlighting the need for ongoing research and the prioritization of clinical trial enrollment when feasible.
Transplant for TP53-mutated MDS and AML: because we can or because we should?
Authors: Versluis Jurjen , Lindsley R. Coleman 
Published: December 2022

Abstract
TP53 mutations impair the cellular response to genotoxic stress and drive intrinsic resistance to conventional cytotoxic therapies. Clinical outcomes in patients with TP53-mutated myeloid malignancies are poor and marked by high-risk clinical features, such as complex karyotype and prior exposure to leukemogenic therapies, and short survival due to a high risk of relapse after allogeneic transplantation. TP53 mutations are thus included as adverse markers in clinical prognostic models, including European LeukemiaNet recommendations and the Molecular International Prognostic Scoring System for myelodysplastic syndromes (MDS). Recent data indicate that the TP53 allelic state, co-occurring somatic mutations, and the position of the TP53 mutation within the clonal hierarchy define genetic heterogeneity among TP53-mutated MDS and acute myeloid leukemia that may influence clinical outcomes, thereby informing the selection of patients most suitable for transplantation. Further, novel therapeutic methods such as antibody-based agents (monoclonals or dual-affinity retargeting antibodies), cellular therapies (natural killer cells, chimeric antigen receptor T cells), or targeted agents (eprenetapopt) may offer opportunities to modify the approach to pretransplant conditioning or posttransplant maintenance and improve clinical outcomes.
The consultant's guide to smoldering multiple myeloma
Authors: Thorsteinsdottir Sigrun , Kristinsson Sigurdur Yngvi 
Published: December 2022

Abstract
Smoldering multiple myeloma (SMM) is an asymptomatic precursor condition to multiple myeloma (MM). The prevalence of SMM is 0.5% in persons over 40 years old; it is higher in men than women and increases with age. When SMM is diagnosed, a thorough diagnostic workup is necessary to exclude myeloma-defining events and stratify patients according to risk of progression to MM. While close monitoring for progression remains the best management for most patients with SMM, in this article, we discuss if treatment initiation before myeloma-defining events occur might be relevant in selected high-risk cases. Two randomized clinical trials have shown a clinical benefit of initiating treatment at the SMM stage, whereof 1 showed an overall survival benefit for those receiving treatment. We discuss various risk stratification models in SMM, important treatment trials, and ongoing trials. Finally, we present how to approach the clinical management of patients with SMM.
Organ function indications and potential improvements following curative therapy for sickle cell disease
Authors: Hulbert Monica L. , King Allison A. , Shenoy Shalini 
Published: December 2022

AbstractCurative therapies for sickle cell disease include allogeneic hematopoietic stem cell transplantation (HSCT) and gene-modified autologous stem cell transplantation. HSCT has been used for 30 years with success measured by engraftment, symptom control, graft-vs-host disease (GVHD) risk, organ toxicity, and immune reconstitution. While human leukocyte antigen–matched sibling donor (MSD) transplants have excellent outcomes, alternate donor transplants (unrelated/haploidentical) are just beginning to overcome GVHD and engraftment hurdles to match MSD. Gene therapy, a newly developed treatment, is undergoing careful evaluation in many trials with varying approaches. The risk/benefit ratio to the patient in relation to outcomes, toxicities, and mortality risk drives eligibility for curative interventions. Consequently, eligibility criteria for MSD transplants can be less stringent, especially in the young. Posttransplant outcome analysis after the “cure” with respect to organ function recovery is essential. While established damage such as stroke is irreversible, transplant can help stabilize (pulmonary function), prevent further deterioration (stroke), improve (neurocognition), and protect unaffected organs. Tracking organ functions postintervention uniformly between clinical trials and for adequate duration is essential to answer safety and efficacy questions related to curative therapies. Age-appropriate application/outcome analyses of such therapies will be the ultimate goal in overcoming this disease.
Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy
Authors: Asare Eugenia Vicky , DeBaun Michael R. , Olayemi Edeghonghon , Boafor Theodore , Oppong Samuel A. 
Published: December 2022

Abstract
Pregnancy in women with sickle cell disease (SCD) is a life-threatening condition. In both high- and low-income countries, there is an 11-fold increased risk of maternal death and a 4-fold increased risk of perinatal death. We highlight the epidemiology of SCD-specific and obstetric complications commonly seen during pregnancy in SCD and propose definitions for acute pain and acute chest syndrome (ACS) episodes during pregnancy. We conducted a systematic review of the recent obstetric and hematology literature using full research articles published within the last 5 years that reported outcomes in pregnant women with SCD. The prevalence of acute pain episodes during pregnancy ranged between 4% and 75%. The prevalence of ACS episodes during pregnancy ranged between 4% and 13%. The estimated prevalence of pulmonary thromboembolism in women with SCD during pregnancy is approximately 0.5 to 1%. ACS is the most common cause of death and is often preceded by acute pain episodes. The most crucial time to develop these complications in pregnancy is during the third trimester and postpartum period. In a pooled analysis from studies in low- and middle-income settings, maternal death in women with SCD is approximately 2393 and 4300 deaths per 100 000 live births with and without multidisciplinary care, respectively. In comparison, in the US and northern Europe, the general maternal mortality rate is approximately 23.8 and 8 deaths per 100 000 live births, respectively. A multidisciplinary SCD obstetrics care approach reduces maternal and perinatal morbidity and mortality in low- and middle-income countries.
Thrombosis questions from the inpatient wards
Authors: Goshua George , Bendapudi Pavan K. , Lee Alfred Ian 
Published: December 2022

Abstract
The multifaceted pathophysiologic processes that comprise thrombosis and thromboembolic diseases take on a particular urgency in the hospitalized setting. In this review, we explore 3 cases of thrombosis from the inpatient wards: purpura fulminans, cancer-associated thrombosis with thrombocytopenia, and coronavirus disease 2019 (COVID-19) and the use of dose-escalated anticoagulation therapy and antiplatelet agents. We discuss the evaluation and management of purpura fulminans and the roles of plasma transfusion, protein C and antithrombin replacement, and anticoagulation in treating this disease. We present a framework for evaluating the etiologies of thrombocytopenia in cancer and review 2 strategies for anticoagulation management in patients with cancer-associated thrombosis and thrombocytopenia, including recent prospective data supporting the use of dose-modified anticoagulation based on platelet count. Last, we dissect the major clinical trials of therapeutic- and intermediate-dose anticoagulation and antiplatelet therapy in hospitalized patients with COVID-19, reviewing key recommendations from consensus guidelines while highlighting ways in which institutional and patient-tailored practices regarding antithrombotic therapies in COVID-19 may differ. Together, the cases highlight the diverse and dramatic presentations of macro- and microvascular thrombosis as encountered on the inpatient wards.
Long-term prophylaxis: what are our options and how to define success?
Authors: Manco-Johnson Marilyn Jean , Warren Beth Boulden 
Published: December 2022

Abstract
Currently, we are at an enviable place in hemophilia treatment. Although full prophylaxis with standard half-life recombinant or plasma-derived factor concentrates has been definitively shown to be inadequate for full protection against bleeding and arthropathy, a number of novel therapies with improved hemostatic enhancement are clinically available or in promising clinical trials. In order to compare outcomes among a number of very efficacious therapies, it is necessary to have sensitive tools employed in long-term follow-up for several years for participants with no or minimal joint disease. The tool kit must be comprehensive, with outcomes of bleeding, factor level restoration or hemostatic capacity, joint structure, joint function, pain, quality of life, and patient satisfaction. This article reviews the history of prophylaxis, the promise of emerging therapies, and the sensitive tools used to assess long-term efficacy for joint structure and function.